Clinical Study
Kinetics and Determining Factors of the Virologic Response to Antiretrovirals during Pregnancy
Table 4
Relationship between virologic response to ARV during pregnancy and selective factors that may affect this response.
| Factor | (%) undetectable | (%) detectable | value |
| Country of origin | | | .16 | US | 39 (80) | 10 (20) | | Mexico | 11 (79) | 3 (21) | | African country | 15 (100) | 0 | | HIV plasma RNA at first visit | | | | 50,000 copies/mL | 6 (75) | 2 (25) | .63 | 50,000 copies/mL | 72 (83) | 15 (17) | | Prepregnancy ARV | | | .27 | Naive | 33 (77) | 10 (23) | | Experienced | 40 (87) | 6 (13) | | TDM | | | .38 | Performed | 53 (79) | 14 (21) | | Not performed | 25 (89) | 3 (11) | | Adherence | | | .006 | 50% | 1 (100) | 0 | | 50% to 95% | 3 (50) | 3 (50) | | 95% | 29 (94) | 2 (6) | | Psychosocial support | | | .01 | Utilized | 63 (89) | 8 (11) | | Not utilized | 15 (63) | 9 (37) | |
|
|